- Home
- ALM vs GYRE Comparison
ALM vs GYRE Comparison
Compare ALM & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALM
- GYRE
- Stock Information
- Founded
- ALM N/A
- GYRE 2002
- Country
- ALM Canada
- GYRE United States
- Employees
- ALM N/A
- GYRE N/A
- Industry
- ALM Other Metals and Minerals
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ALM Basic Materials
- GYRE Health Care
- Exchange
- ALM Nasdaq
- GYRE Nasdaq
- Market Cap
- ALM 958.4M
- GYRE 897.1M
- IPO Year
- ALM N/A
- GYRE N/A
- Fundamental
- Price
- ALM $4.28
- GYRE $8.18
- Analyst Decision
- ALM Strong Buy
- GYRE
- Analyst Count
- ALM 2
- GYRE 0
- Target Price
- ALM $7.00
- GYRE N/A
- AVG Volume (30 Days)
- ALM 926.9K
- GYRE 77.8K
- Earning Date
- ALM 08-14-2025
- GYRE 08-11-2025
- Dividend Yield
- ALM N/A
- GYRE N/A
- EPS Growth
- ALM N/A
- GYRE N/A
- EPS
- ALM N/A
- GYRE 0.02
- Revenue
- ALM $20,657,545.00
- GYRE $102,189,000.00
- Revenue This Year
- ALM $143.16
- GYRE $21.04
- Revenue Next Year
- ALM $126.76
- GYRE $89.64
- P/E Ratio
- ALM N/A
- GYRE $176.20
- Revenue Growth
- ALM 9.87
- GYRE N/A
- 52 Week Low
- ALM $3.16
- GYRE $6.11
- 52 Week High
- ALM $5.50
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ALM N/A
- GYRE 58.07
- Support Level
- ALM N/A
- GYRE $7.35
- Resistance Level
- ALM N/A
- GYRE $8.30
- Average True Range (ATR)
- ALM 0.00
- GYRE 0.45
- MACD
- ALM 0.00
- GYRE 0.08
- Stochastic Oscillator
- ALM 0.00
- GYRE 92.86
About ALM Almonty Industries Inc. Common Shares
Almonty Industries Inc is engaged in the mining, processing, and shipping of tungsten concentrate from its Los Santos tungsten mine located near Salamanca, Spain - the Los Santos Mine, the processing and shipping of tungsten concentrate from its Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal - the Panasqueira Mine, the evaluation of its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora - the Valtreixal Mine, as well as the exploration and evaluation of its Sangdong tungsten mine project located in Gangwon Province, Republic of Korea - the Sangdong Mine.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.